A 52-week, Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (AURORA)

Status

Suspended

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506174-12-00

Acronym

TCD601H101

Enrollment

Registered

2023-12-14

Start date

2024-04-03

Completion date

Unknown

Last updated

2025-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis

None listed

Sex/Gender

All

Age

18 Years to No maximum

Sweden

None listed

Source: EU CTIS · Data processed: Feb 4, 2026